<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.0" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CEP</journal-id>
<journal-title-group>
<journal-title>Clinical and Experimental Pediatrics</journal-title><abbrev-journal-title>Clin Exp Pediatr</abbrev-journal-title></journal-title-group>
<issn pub-type="epub">2713-4148</issn>
<publisher>
<publisher-name>Korean Pediatric Society</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3345/cep.2026.00388</article-id>
<article-id pub-id-type="publisher-id">cep-2026-00388</article-id>
<article-categories>
<subj-group>
<subject>Original Article</subject></subj-group></article-categories>
<title-group>
<article-title>Impact of bacterial infection on native liver survival in children with cirrhosis due to biliary atresia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0009-0003-3598-0280</contrib-id>
<name><surname>Kaewchaivijit</surname><given-names>Varissara</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="af1-cep-2026-00388"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9374-8805</contrib-id>
<name><surname>Tanpowpong</surname><given-names>Pornthep</given-names></name>
<degrees>MD</degrees>
<degrees>MPH</degrees>
<xref ref-type="corresp" rid="c1-cep-2026-00388"/>
<xref ref-type="aff" rid="af1-cep-2026-00388"><sup>1</sup></xref>
<xref ref-type="aff" rid="af2-cep-2026-00388"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7558-1995</contrib-id>
<name><surname>Getsuwan</surname><given-names>Songpon</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="af1-cep-2026-00388"><sup>1</sup></xref>
<xref ref-type="aff" rid="af2-cep-2026-00388"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2504-5462</contrib-id>
<name><surname>Boonsathorn</surname><given-names>Sophida</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="af3-cep-2026-00388"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6838-2656</contrib-id>
<name><surname>Lertudomphonwanit</surname><given-names>Chatmanee</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="af1-cep-2026-00388"><sup>1</sup></xref>
<xref ref-type="aff" rid="af2-cep-2026-00388"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6651-2282</contrib-id>
<name><surname>Treepongkaruna</surname><given-names>Suporn</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="af1-cep-2026-00388"><sup>1</sup></xref>
<xref ref-type="aff" rid="af2-cep-2026-00388"><sup>2</sup></xref>
</contrib>
<aff id="af1-cep-2026-00388">
<label>1</label>Division of Gastroenterology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, <country>Thailand</country></aff>
<aff id="af2-cep-2026-00388">
<label>2</label>Ramathibodi Excellence Center in Organ Transplantation, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, <country>Thailand</country></aff>
<aff id="af3-cep-2026-00388">
<label>3</label>Division of Infectious diseases, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, <country>Thailand</country></aff>
</contrib-group>
<author-notes>
<corresp id="c1-cep-2026-00388">Corresponding author: Pornthep Tanpowpong, MD, MPH. Division of Gastroenterology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand Email: <email>pornthep.tan@mahidol.ac.th</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>7</month>
<year>2026</year></pub-date>
<elocation-id>cep.2026.00388</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>02</month>
<year>2026</year></date>
<date date-type="rev-recd">
<day>14</day>
<month>06</month>
<year>2026</year></date>
<date date-type="accepted">
<day>15</day>
<month>06</month>
<year>2026</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x000a9; 2026 by The Korean Pediatric Society</copyright-statement>
<copyright-year>2026</copyright-year>
<license>
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions>
<abstract>
<sec><title>Background</title>
<p> Biliary atresia (BA) is a common cause of cirrhosis in children, and serious bacterial infections may worsen clinical outcomes.</p></sec>
<sec><title>Purpose</title>
<p> To study the characteristics, associated factors, and outcomes of infections in children with cirrhosis secondary to BA.</p></sec>
<sec><title>Methods</title>
<p> A retrospective cohort study was conducted in children aged &lt;18 years with cirrhosis due to BA between 2014 and 2023. Patients were categorized as having proven/suspected bacterial infection, presumed viral infection, or no documented infection. The clinical characteristics, associated risk factors, predictive models, and native liver survival outcomes, including liver transplantation (LT) and death, were analyzed.</p></sec>
<sec><title>Results</title>
<p> Among 150 children, 94 (62.7%) had 222 infection episodes and 249 had infection-related diagnosis. Of the 222 episodes, 143 (64.4%) were classified as proven/suspected bacterial infections; cholangitis was the most common bacterial diagnosis (39.7%). Univariate analysis showed that proven/suspected bacterial infection was associated with higher pediatric end-stage liver disease scores at the first visit and during fever episodes and with higher total and direct bilirubin levels during fever episodes. C-reactive protein (CRP) cutoff of 31 mg/L yielded 75.4% sensitivity, 68.2% specificity, and an area under the receiver operating characteristic curve of 0.80 (95% confidence interval [CI], 0.69&#x02013;0.90) for distinguishing proven/suspected bacterial from presumed viral infections. Overall, 54% of patients underwent LT, 24% survived with their native liver, 8% died, and 14% were lost to follow-up. After adjustment for disease severity and infection history before referral, proven/suspected bacterial infection was associated with lower native liver survival (adjusted hazard ratio, 1.88; 95% CI, 1.51&#x02013;2.33).</p></sec>
<sec><title>Conclusion</title>
<p> Infections are common in children with cirrhosis due to BA. Serum CRP may help distinguish proven/suspected bacterial from other infections. Bacterial infections were associated with lower native liver survival; therefore, appropriate management and prevention may improve native liver survival.</p></sec>
</abstract>
<kwd-group>
<kwd>Bacterial infection</kwd>
<kwd>Chronic liver disease</kwd>
<kwd>C-reactive protein</kwd>
<kwd>Native liver survival</kwd>
<kwd>Liver transplantation</kwd>
</kwd-group>
</article-meta>
<notes>
<title>Key message</title>
<boxed-text>
<p><bold>Question:</bold> Are bacterial infections associated with lower native liver survival in children with biliary atresia (BA)?</p>
<p><bold>Finding:</bold> Children with BA and proven/suspected bacterial infections, including cholangitis, had significantly lower native liver survival and higher rates of liver transplantation or death.</p>
<p><bold>Meaning:</bold> Early recognition, appropriate management, and prevention of bacterial infections may improve native liver survival in children with BA-related cirrhosis.</p>
</boxed-text>
</notes></front>
<body>
<p><xref rid="f2-cep-2026-00388" ref-type="fig"/></p>
<p><bold>Graphical abstract.</bold> CRP, C-reactive protein; AUC, area under the curve; HR, hazard ratio; CI, confidence interval.</p>
<sec sec-type="intro">
<title>Introduction</title>
<p>Cirrhosis is one of the long-term sequelae of biliary atresia (BA) in pediatric patients &#x0005b;<xref ref-type="bibr" rid="b1-cep-2026-00388">1</xref>&#x0005d;. Children with BA with delayed diagnosis or could not have adequate bile flow after hepatic portoenterostomy (also known as Kasai operation) generally experience several cirrhosis-related complications such as portal hypertension and variceal bleeding, delayed growth, and malnutrition &#x0005b;<xref ref-type="bibr" rid="b2-cep-2026-00388">2</xref>&#x0005d;. Furthermore, a number of children with cirrhosis can also develop potential infection-related life-threatening conditions such as acute cholangitis, spontaneous bacterial peritonitis (SBP), and sepsis/bacteremia &#x0005b;<xref ref-type="bibr" rid="b2-cep-2026-00388">2</xref>&#x0005d;. Multifactorial pathogenic mechanisms can exert an excessive inflammatory response and thus induce circulatory dysfunction and acute decompensation that leads to morbidity and death &#x0005b;<xref ref-type="bibr" rid="b3-cep-2026-00388">3</xref>&#x0005d;.</p>
<p>While there have been numerous studies exploring the characteristics of infections in adult patients with cirrhosis, there is a lack of research in children. The characterization of impact of infections such as septicemia &#x0005b;<xref ref-type="bibr" rid="b4-cep-2026-00388">4</xref>,<xref ref-type="bibr" rid="b5-cep-2026-00388">5</xref>&#x0005d;, SBP &#x0005b;<xref ref-type="bibr" rid="b6-cep-2026-00388">6</xref>&#x0005d;, acute cholangitis &#x0005b;<xref ref-type="bibr" rid="b7-cep-2026-00388">7</xref>&#x0005d;, infected biloma in children with BA &#x0005b;<xref ref-type="bibr" rid="b8-cep-2026-00388">8</xref>,<xref ref-type="bibr" rid="b9-cep-2026-00388">9</xref>&#x0005d;, and urinary tract infection have been reported &#x0005b;<xref ref-type="bibr" rid="b10-cep-2026-00388">10</xref>&#x0005d;. However, these children can also suffer from other common viral infections such as upper and lower respiratory tract infections, otitis media, and acute gastroenteritis. The incidence of various infections in the tropical countries may be even higher when compared to a report from westernized countries &#x0005b;<xref ref-type="bibr" rid="b11-cep-2026-00388">11</xref>&#x0005d;. The evaluation for potential etiologies can therefore be challenging, time-consuming and labor-intensive which can also make the management more difficult or further delayed when compared to the children without cirrhosis. A recent study by Shiau et al. &#x0005b;<xref ref-type="bibr" rid="b12-cep-2026-00388">12</xref>&#x0005d; also found that age at Kasai operation and platelet count are risk factors for serious infections.</p>
<p>Moreover, as signs and symptoms can be nonspecific, several biomarkers including C-reactive protein (CRP) &#x0005b;<xref ref-type="bibr" rid="b13-cep-2026-00388">13</xref>&#x0005d;, procalcitonin &#x0005b;<xref ref-type="bibr" rid="b14-cep-2026-00388">14</xref>&#x0005d;, or interleukin (IL)-6 &#x0005b;<xref ref-type="bibr" rid="b15-cep-2026-00388">15</xref>&#x0005d;, have been used to aid and differentiate serious bacterial infection with other less severe infections in patients with cirrhosis; but the yield of the aforementioned markers remain inconclusive &#x0005b;<xref ref-type="bibr" rid="b12-cep-2026-00388">12</xref>&#x0005d;. In adults, septic patients with pneumonia or &gt;1 site of infection had a higher mortality &#x0005b;<xref ref-type="bibr" rid="b16-cep-2026-00388">16</xref>&#x0005d;. A recent study by Singh et al. found that ascites fluid infection (AFI) was found in 31% children with chronic liver disease and almost half of them were nosocomial infection resulting in high mortality. It was also concluded that children with AFI and worsening cirrhosis should be evaluated for liver transplantation (LT) &#x0005b;<xref ref-type="bibr" rid="b17-cep-2026-00388">17</xref>&#x0005d;. Children with cirrhosis who develop several episodes of cholangitis and septicemia are also at risk for LT18) and death &#x0005b;<xref ref-type="bibr" rid="b11-cep-2026-00388">11</xref>,<xref ref-type="bibr" rid="b12-cep-2026-00388">12</xref>&#x0005d;.</p>
<p>With the limited data on this regard in children with BA with cirrhosis, therefore we aimed to study on the characteristics of infection, evaluation and management, potential risk factors for developing infection, clinical outcomes, which remain a gap in the current knowledge. Such studies would likely provide benefits for patient care in effectively managing BA children presenting with suspected infection and possibly leading to an improved prognosis.</p>
</sec>
<sec sec-type="methods">
<title>Methods</title>
<sec>
<title>1. Study design, population, and data collection</title>
<p>A single-center retrospective cohort study was performed at the Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand, a tertiary care teaching hospital with an active LT program for children. The study protocol was approved by the Human Research Ethics Committee of the Faculty of Medicine Ramathibodi Hospital, Mahidol University (approval no. MURA2023/951). The requirement for informed consent was waived because of the retrospective nature of the study. Data collection was performed via electronic medical records and hospital database (International Classification of Diseases, 10th Revision &#x0005b;ICD-10&#x0005d; of Q442) for a period of 10 years (January 2014 to December 2023) in patients age less than 18 years who were diagnosed with cirrhosis due to BA. Patients were excluded if a significant portion of clinical data was missing (e.g., missing primary outcome, missing infection status). Infection episodes were excluded if they were classified as hospital-acquired infections.</p>
<p>According to our objective, we primarily aimed to study pre-LT related infections in patients with cirrhosis due to BA when they presented with fever in outpatient or emergency department. Data included demographic information, underlying condition including severity and complications of cirrhosis, other medical conditions such as acute kidney injury and variceal bleeding. Significant portal hypertension was defined if the patient had evidence of varices, ascites, or thrombocytopenia with splenomegaly &#x0005b;<xref ref-type="bibr" rid="b18-cep-2026-00388">18</xref>&#x0005d;. Data on infections including types of infection, diagnosis, clinical courses, laboratory investigations (e.g., CRP, procalcitonin) and treatment. Clinical outcomes were recorded included with LT, survival with native liver, death, or loss to follow-up. These data were retrieved since the diagnosis of BA until either the point of predefined clinical outcome or the last day of followup. Other interested outcomes were the recurrence of infections, worsening liver synthetic function, and complications of cirrhosis such as portal hypertension or variceal bleeding.</p>
</sec>
<sec>
<title>2. Definition of proven/suspected bacterial infections</title>
<p>Various proven/suspected bacterial infections would be categorized as a clinically compatible infectious syndrome diagnosed by the treating physician and/or supported by positive-microbiological confirmation into one of the following: Hepatobiliary infection including; acute cholangitis was defined by the Tokyo guideline 2018 criteria as suspected diagnosis and definite diagnosis &#x0005b;<xref ref-type="bibr" rid="b19-cep-2026-00388">19</xref>&#x0005d;. Infected biloma was defined by fever with/without increasing jaundice and the evidence of biloma by imaging (liver ultrasonography or computed tomography of the abdomen) &#x0005b;<xref ref-type="bibr" rid="b20-cep-2026-00388">20</xref>&#x0005d;. AFI; SBP was defined by polymorphonuclear cells &gt;250 mm<sup>3</sup> in the ascitic fluid with positive culture, culture-negative neutrocytic ascites was defined by polymorphonuclear cells &gt;250 mm<sup>3</sup> with negative ascitic culture in the absence of previous antibiotic administration, and monomicrobial non-neutrocytic bacterascites was defined by polymorphonuclear cells &lt;250 mm<sup>3</sup> with positive ascitic fluid culture &#x0005b;<xref ref-type="bibr" rid="b21-cep-2026-00388">21</xref>&#x0005d;. &#x02018;Bacteremia/septicemia&#x02019; was defined by fever with positive blood culture &#x0005b;<xref ref-type="bibr" rid="b22-cep-2026-00388">22</xref>&#x0005d;. Infectious diarrhea was defined by diarrhea with positive stool culture for enteropathogenic organisms or pathogenic bacteria detected by polymerase chain reaction-based stool tests &#x0005b;<xref ref-type="bibr" rid="b23-cep-2026-00388">23</xref>&#x0005d;. Urinary tract infection was defined by fever, pyuria with white blood cells &#x02265;5/high power field or positive leukocyte esterase and/or positive nitrite with positive urine culture &#x0005b;<xref ref-type="bibr" rid="b24-cep-2026-00388">24</xref>&#x0005d;. The aforementioned bacterial infections were common in BA patients based on the previous study &#x0005b;<xref ref-type="bibr" rid="b12-cep-2026-00388">12</xref>&#x0005d;.</p>
</sec>
<sec>
<title>3. Definition of presumed viral infections</title>
<p>Presumed viral infection was defined as febrile manifestation and negative for bacterial culture or strong evidence for suspected bacterial infection (e.g., acute cholangitis) with or without positive viral antigen or polymerase chain reaction &#x0005b;<xref ref-type="bibr" rid="b12-cep-2026-00388">12</xref>&#x0005d;. Of note, one fever episode could have &gt;1 positive test for either bacteria or viral infection or both, and if they had at least 1 diagnosis of proven/suspected bacterial infection, that fever episode was categorized as bacterial infection.</p>
</sec>
<sec>
<title>4. Biostatistical analysis</title>
<p>We performed descriptive statistics to summarize the characteristics, incidence, and types of infection of the study population. Statistical analyses were conducted by using chi-square test or student <italic>t</italic> test to identify significant associations between risk factors and infections. The Cox proportion hazard model with multiple record and multiple events (applying the covariates, fixed effect) was performed for comparing survival rate between proven/suspected bacterial infection versus presumed viral infection to LT and death.</p>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>1. Baseline characteristics</title>
<p>Patients were identified from the hospital database using the ICD-10 code Q442 over a 10-year period, yielding a total of 201 cases, and 50 patients were excluded (<xref rid="SD1-cep-2026-00388" ref-type="supplementary-material">Supplementary Fig. 1</xref>). Therefore, the total number of patients were 150 patients (females 51.3%, underwent Kasai operation 72%, mean age of the first visit to our center of 6 months, and decompensated cirrhosis in 77.2%). Patients can be categorized into 3 infection-related groups: proven or suspected bacterial infection (n&#x0003d;65), presumed viral infection (n&#x0003d;29), and no documented infection (n&#x0003d;56) as shown in <xref rid="t1-cep-2026-00388" ref-type="table">Table 1</xref>. The median follow-up duration was 10.2 months to clinical outcomes including LT, survival with native liver, death, and loss to follow-up. No statistically significant differences of each variable were observed among groups with regards to demographics and baseline clinical condition/severity.</p>
</sec>
<sec>
<title>2. Infection episodes and diagnosis</title>
<p>A total of 222 fever episodes resulted in 249 infection-related diagnoses, with 64.4% (N&#x0003d;143) classified as proven or suspected bacterial infections and 35.6% (N&#x0003d;79) categorized as presumed viral infections (<xref rid="t2-cep-2026-00388" ref-type="table">Table 2</xref>). Twenty-seven fever episodes had &gt;1 infection-related diagnosis. Among bacterial infections, the most common diagnoses were acute cholangitis, followed by bacteremia/septicemia, infected biloma, and AFI. Other notable bacterial infections included infectious diarrhea, urinary tract infection, and liver abscesses. Presumed viral infections included gastroenteritis, respiratory tract infections, and others such as exanthem, herpangina.</p>
</sec>
<sec>
<title>3. Factors associated with proven or suspected bacterial infection</title>
<p>Four factors were associated with cases with proven or suspected bacterial infection: pediatric end-stage liver disease (PELD) score at the first visit, PELD score at the fever episode, total bilirubin, and direct bilirubin levels during the fever episode (<xref rid="t3-cep-2026-00388" ref-type="table">Table 3</xref>). In the multivariate analysis, after adjusting for potential confounders, only total bilirubin at the fever episode remained a significant predictor of bacterial infection (hazard ratio &#x0005b;HR&#x0005d; 1.73, 95% confidence interval &#x0005b;CI&#x0005d;, 1.09&#x02013;2.76, <italic>P</italic>&#x0003d;0.021). However, due to significantly high collinearity with PELD score and bilirubin levels, these variables could not be included in the multivariate analysis.</p>
</sec>
<sec>
<title>4. Factors associated proven or suspected bacterial infection (fever episodes)</title>
<p>In the univariate analysis, several factors were found to be associated with episodes of proven or suspected bacterial infection including anemia (defined by hemoglobin &lt;11 g/dL), elevated CRP and PELD score at the time of fever episode. In the multivariate analysis, 2 factors remained an independent predictor: CRP and PELD score (<xref rid="t4-cep-2026-00388" ref-type="table">Table 4</xref>). Other variables such as high-grade fever, change of mental status, shock, abnormal white blood cell counts (leukocytosis or leukopenia), thrombocytopenia, elevated procalcitonin, and hypoalbuminemia were not statistically significant.</p>
</sec>
<sec>
<title>5. CRP to distinguish proven/suspected bacterial infection from presumed viral infection</title>
<p>To be able to differentiate bacterial versus viral infection at the fever episode, CRP as the only significant independent predictor among the biomarkers in the regression analysis was applied to quantify the impact of variability among individuals&#x02019; decision thresholds. The receiver operating characteristic (ROC) curve showed a good diagnostic performance of CRP with an optimal cutoff of 31 mg/L, yielding an area under the ROC curve of 0.80 (95% CI, 0.69&#x02013;0.90) as shown in <xref rid="SD2-cep-2026-00388" ref-type="supplementary-material">Supplementary Fig. 2</xref>. At this cutoff, CRP demonstrated a sensitivity of 75.4% and specificity of 68.2%. The positive predictive value and negative predictive value were 87.5% and 93.8%, respectively, with an overall accuracy of 73%.</p>
</sec>
<sec>
<title>6. Independent factors contributing to the chance of undergoing LT</title>
<p><xref rid="t5-cep-2026-00388" ref-type="table">Table 5</xref> presents univariate and multivariate Cox regression analyses to identify factors associated with LT. In the univariate analysis, proven or suspected bacterial infection, and elevated PELD score at the first visit to our center and last visit were both associated with a higher chance of LT. However, only proven or suspected bacterial infection remained an independent predictor of LT. Not only for LT, but mortality also affected by bacterial infection with an adjusted HR of 51.03 (<italic>P</italic>&lt;0.001).</p>
</sec>
<sec>
<title>7. Impact of bacterial infection on native liver survival</title>
<p>Patients with proven or suspected bacterial infection had significantly poorer native liver survival (i.e., more LT or death) compared to those without documented bacterial infection. The survival probability in the bacterial infection group (dashed red line) declined rapidly, particularly within the first 6 months after the first visit (vertical red line), whereas the nonbacterial infected group (solid blue line) demonstrated a more sustained native liver function over time. The probability of native liver survival dropped to approximately 25% at 6 months in children previously suffered from bacterial infection while the ones without bacterial infection had a chance of maintaining a native liver status at 80%. The HR for loss of native liver in the presence of bacterial infection was 1.88 (95% CI, 1.51&#x02013;2.33), indicating a nearly twofold increased risk (<xref rid="f1-cep-2026-00388" ref-type="fig">Fig. 1</xref>).</p>
<p>The clinical factors associated with outcomes in children with BA, categorized into 4 groups: LT (n&#x0003d;81), survived with native liver (n&#x0003d;36), death (n&#x0003d;12), and loss to follow-up (n&#x0003d;21). A significantly higher proportion of patients in the native liver group were the ones who underwent Kasai operation (94.4%) was noted, when compared to the LT group (65.4%) (<italic>P</italic>&#x0003d;0.008), similarly to as the presence of decompensated cirrhosis (<italic>P</italic>&lt;0.001) (<xref rid="t6-cep-2026-00388" ref-type="table">Table 6</xref>). PELD score at the first visit also varied significantly across the 4 groups (<italic>P</italic>&lt;0.001). Other variables, such as sex, age at Kasai operation after 90 days, and history of past infection before referral to our center did not show statistically significant differences among groups.</p>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>In a single-center cohort of BA children with cirrhosis, bacterial infections were common, with cholangitis being the most common bacterial infection, accounting for nearly 40% of total bacterial infection. Other liver disease-related infections such as infected biloma and AFI were also relatively common in our population. While comparing between the 3 groups (bacterial infection, viral infection, and no infection), no statistically significant differences of demographics, performed Kasai operation, or baseline clinical condition were observed. This finding is consistent with a study from Taiwan &#x0005b;<xref ref-type="bibr" rid="b12-cep-2026-00388">12</xref>&#x0005d; that reported cholangitis in 46.2% of post-Kasai patients, reinforcing its role as a leading infectious complication in this population.</p>
<p>Bacterial infections were associated with significantly higher PELD scores both at the first visit and the fever episode as well as bilirubin levels as a person-related data (<xref rid="t3-cep-2026-00388" ref-type="table">Table 3</xref>). These parameters reflect the severity of liver dysfunction in these children with chronic liver disease. Similarly, Bolia et al. &#x0005b;<xref ref-type="bibr" rid="b25-cep-2026-00388">25</xref>&#x0005d; demonstrated that a higher Child-Pugh score, along with lower serum albumin and elevated international normalized ratio, was associated with an increased risk of infection in children with acute liver failure and decompensated chronic liver disease. This finding was parallel between Child-Pugh and PELD scores across different studies emphasizing the relevance of liver disease severity in predisposing to various types of infections. Cirrhosis is an immunomodulatory deficiency state &#x0005b;<xref ref-type="bibr" rid="b26-cep-2026-00388">26</xref>&#x0005d;, predisposing such patients to other various infections through multiple mechanisms &#x0005b;<xref ref-type="bibr" rid="b19-cep-2026-00388">19</xref>,<xref ref-type="bibr" rid="b27-cep-2026-00388">27</xref>&#x0005d;, such as bacterial overgrowth and small intestinal barrier dysfunction resulting in further bacterial translocation &#x0005b;<xref ref-type="bibr" rid="b4-cep-2026-00388">4</xref>,<xref ref-type="bibr" rid="b6-cep-2026-00388">6</xref>,<xref ref-type="bibr" rid="b27-cep-2026-00388">27</xref>,<xref ref-type="bibr" rid="b28-cep-2026-00388">28</xref>&#x0005d;. Genetic variants in those with cirrhosis have also been noted to be associated with an increased risk and severity of infection &#x0005b;<xref ref-type="bibr" rid="b29-cep-2026-00388">29</xref>&#x0005d;.</p>
<p>From <xref rid="t4-cep-2026-00388" ref-type="table">Table 4</xref> as described the infection episode-related data, CRP and PELD score were 2 significant independent associated factors of proven/suspected bacterial infection (vs. presumed viral infection). Other clinical and laboratory parameters such as high-grade fever, abnormal blood cell indices, procalcitonin or hypoalbuminemia were not statistically significant. A recent study by Shiau et al. &#x0005b;<xref ref-type="bibr" rid="b12-cep-2026-00388">12</xref>&#x0005d; also found that platelet count is one of the risk factors for future serious infections. From our study, CRP levels showed good discriminatory power with an area under the ROC curve of 0.80 at a cutoff of 31 mg/L, yielding an accuracy of 73%. This finding may support the clinical utility of CRP as a biomarker for an identification of bacterial infection in this population. However, this cutoff value is notably higher than those reported in previous pediatric studies. For instance, Bolia et al. &#x0005b;<xref ref-type="bibr" rid="b30-cep-2026-00388">30</xref>&#x0005d; and Kalvandi et al. &#x0005b;<xref ref-type="bibr" rid="b31-cep-2026-00388">31</xref>&#x0005d; reported an optimal threshold of 6 mg/L in children with acute liver failure, decompensated chronic liver disease, or ascites, with good diagnostic performance for bacterial infections and mainly for SBP. Similarly, Deutsch et al. &#x0005b;<xref ref-type="bibr" rid="b13-cep-2026-00388">13</xref>&#x0005d; demonstrated that a CRP cutoff of 10 mg/L was appropriate for detecting bacterial infections in adult patients with cirrhosis. This relatively high CRP threshold and limited number of documented test maybe due to that CRP was being performed selectively in cases with more severe clinical presentations and/or when followup of treatment response was deemed necessary by the treating physician.</p>
<p>We found that native liver survival was significantly reduced in patients with bacterial infection (adjusted HR, 1.88), reinforcing the role of infection in liver function deterioration and loss of transplant-free survival. Although a higher PELD score was associated with an increased risk of death and transplantation in the univariate analysis, it did not retain statistical significance in the multivariable analysis (<xref rid="t5-cep-2026-00388" ref-type="table">Table 5</xref>). These findings highlight the detrimental effect of bacterial infection on the preservation of native liver function and suggest that the management of bacterial infection may likely be crucial in improving long-term liver outcomes &#x0005b;<xref ref-type="bibr" rid="b27-cep-2026-00388">27</xref>&#x0005d;. Based on our results and existing evidence, cholangitis is the most common cause of proven/suspected bacterial infection in children with BA, likely related to previous Kasai portoenterostomy. Moreover, our study demonstrated that, after adjusting for disease severity scores and prior history of infection before referral, proven/suspected bacterial infection was associated with a lower probability of native liver survival (i.e., higher rates of LT or death). However, there is currently dearth of studies evaluating the clinical outcomes in patients with BA and cirrhosis after bacterial infections. Therefore, this aspect reported in the present study addresses the existing knowledge gap.</p>
<p>This study examined infections in a relatively large cohort of children with BA, encompassing not only bacterial infections but also viral infectious etiologies. We evaluated the utility of clinical and laboratory parameters in differentiating bacterial infections from other infections, and to explore the clinical outcomes associated with bacterial infections. However, several limitations should be acknowledged. First, the retrospective design inherently limits data completeness, and missing data were unavoidable. In addition, data collection was limited to the &#x02018;documented&#x02019; infection episodes, resulting in inconsistent timing across patients and preventing longitudinal assessment of changes in clinical status or risk factors over time. Accordingly, this may have contributed to the relatively high proportion of patients classified into the &#x0201c;no documented infection&#x0201d; group. The CRP was measured in just 40% of the total infection episodes as it may be due to that CRP was performed based on clinical indication and selectively checked in cases with more severe clinical presentations or those mostly diagnosed with proven/suspected bacterial infections. Patients with milder clinical presentations, such as low-grade fever, viral illness, or upper respiratory tract infections, were less likely to undergo CRP testing. Therefore, we acknowledge this as a limitation in this retrospective study. The median follow-up duration was approximately 10 months, which may be considered relatively short. This is largely attributable to the fact that most patients in this cohort were referred for LT, and the evaluation and treatment process was typically completed within a relatively short timeframe.</p>
<p>In conclusion, infections mainly cholangitis and bacteremia are common in children with cirrhosis due to BA. A higher PELD score at the first visit and during febrile episodes, as well as elevated bilirubin levels, were significantly associated with proven or suspected bacterial infection. Specific clinical and laboratory parameters, such as CRP, are useful in differentiating bacterial infections from other causes of fever. Bacterial infection was also associated with a decreased early survival rate. Developing appropriate strategies to manage and prevent such bacterial infections could improve clinical outcomes.</p>
</sec>
</body>
<back>
<sec sec-type="supplementary-material"><title>Supplementary materials</title>
<p>Supplementary Figs. 1-2 are available at <ext-link xlink:href="https://doi.org/10.3345/cep.2026.00388" ext-link-type="uri">https://doi.org/10.3345/cep.2026.00388</ext-link>.</p>
<supplementary-material content-type="loca-data" id="SD1-cep-2026-00388">
<label>Supplementary Fig. 1.</label><caption><p>Flowchart of the study population. ICD-10, International Classification of Diseases, 10th Revision; BA, biliary atresia.</p></caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="cep-2026-00388-Supplementary-Fig-1.pdf"/></supplementary-material>
<supplementary-material content-type="loca-data" id="SD2-cep-2026-00388">
<label>Supplementary Fig. 2.</label><caption><p>C-reactive protein in distinguishing proven/suspected bacterial infections from other infections during febrile episodes.</p></caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="cep-2026-00388-Supplementary-Fig-2.pdf"/></supplementary-material>
</sec>
<fn-group>
<fn fn-type="conflict"><p><bold>Conflicts of interest</bold></p><p>No potential conflict of interest relevant to this article was reported.</p></fn>
<fn fn-type="financial-disclosure"><p><bold>Funding</bold></p><p>This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></fn>
<fn fn-type="other"><p><bold>Acknowledgments</bold></p><p>PT received a Career Development Grant from Faculty of Medicine, Ramathibodi Hospital, but this grant did not support the present study.</p></fn>
<fn fn-type="participating-researchers"><p><bold>Author contribution</bold></p><p>Conceptualization: VK, PT, SB, CL, ST; Data curation: VK; Formal analysis: VK; Methodology: VK, PT, SG, SB, CL, ST; Writing - original draft: VK; Writing - review &amp; editing: PT, SG, SB, CL, ST</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="b1-cep-2026-00388">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Scottoni</surname><given-names>F</given-names></name>
<name><surname>Davenport</surname><given-names>M</given-names></name>
</person-group>
<article-title>Biliary atresia: potential for a new decade</article-title>
<source>Semin Pediatr Surg</source>
<year>2020</year>
<volume>29</volume>
<fpage>150940</fpage>
</element-citation></ref>
<ref id="b2-cep-2026-00388">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pinto</surname><given-names>RB</given-names></name>
<name><surname>Schneider</surname><given-names>AC</given-names></name>
<name><surname>da Silveira</surname><given-names>TR</given-names></name>
</person-group>
<article-title>Cirrhosis in children and adolescents: an overview</article-title>
<source>World J Hepatol</source>
<year>2015</year>
<volume>7</volume>
<fpage>392</fpage>
<lpage>405</lpage>
</element-citation></ref>
<ref id="b3-cep-2026-00388">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ekpanyapong</surname><given-names>S</given-names></name>
<name><surname>Reddy</surname><given-names>KR</given-names></name>
</person-group>
<article-title>Infections in cirrhosis</article-title>
<source>Curr Treat Options Gastroenterol</source>
<year>2019</year>
<volume>17</volume>
<fpage>254</fpage>
<lpage>70</lpage>
</element-citation></ref>
<ref id="b4-cep-2026-00388">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bunchorntavakul</surname><given-names>C</given-names></name>
<name><surname>Chamroonkul</surname><given-names>N</given-names></name>
<name><surname>Chavalitdhamrong</surname><given-names>D</given-names></name>
</person-group>
<article-title>Bacterial infections in cirrhosis: a critical review and practical guidance</article-title>
<source>World J Hepatol</source>
<year>2016</year>
<volume>8</volume>
<fpage>307</fpage>
<lpage>21</lpage>
</element-citation></ref>
<ref id="b5-cep-2026-00388">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Taneja</surname><given-names>SK</given-names></name>
<name><surname>Dhiman</surname><given-names>RK</given-names></name>
</person-group>
<article-title>Prevention and management of bacterial infections in cirrhosis</article-title>
<source>Int J Hepatol</source>
<year>2011</year>
<volume>2011</volume>
<fpage>784540</fpage>
</element-citation></ref>
<ref id="b6-cep-2026-00388">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Larcher</surname><given-names>VF</given-names></name>
<name><surname>Manolaki</surname><given-names>N</given-names></name>
<name><surname>Vegnente</surname><given-names>A</given-names></name>
<name><surname>Vergani</surname><given-names>D</given-names></name>
<name><surname>Mowat</surname><given-names>AP</given-names></name>
</person-group>
<article-title>Spontaneous bacterial peritonitis in children with chronic liver disease: clinical features and etiologic factors</article-title>
<source>J Pediatr</source>
<year>1985</year>
<volume>106</volume>
<fpage>907</fpage>
<lpage>12</lpage>
</element-citation></ref>
<ref id="b7-cep-2026-00388">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>JY</given-names></name>
<name><surname>Lim</surname><given-names>LT</given-names></name>
<name><surname>Quak</surname><given-names>SH</given-names></name>
<name><surname>Prabhakaran</surname><given-names>K</given-names></name>
<name><surname>Aw</surname><given-names>M</given-names></name>
</person-group>
<article-title>Cholangitis in children with biliary atresia: health-care resource utilisation</article-title>
<source>J Paediatr Child Health</source>
<year>2014</year>
<volume>50</volume>
<fpage>196</fpage>
<lpage>201</lpage>
</element-citation></ref>
<ref id="b8-cep-2026-00388">
<label>8</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<name><surname>Balfour</surname><given-names>J</given-names></name>
<name><surname>Desai</surname><given-names>H</given-names></name>
<name><surname>Ewing</surname><given-names>A</given-names></name>
</person-group>
<article-title>Hepatic Biloma</article-title>
<comment>2025 Nov 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-</comment>
</element-citation></ref>
<ref id="b9-cep-2026-00388">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jab&#x00142;o&#x00144;ska</surname><given-names>B</given-names></name>
<name><surname>Lampe</surname><given-names>P</given-names></name>
</person-group>
<article-title>Iatrogenic bile duct injuries: etiology, diagnosis and management</article-title>
<source>World J Gastroenterol</source>
<year>2009</year>
<volume>15</volume>
<fpage>4097</fpage>
<lpage>104</lpage>
</element-citation></ref>
<ref id="b10-cep-2026-00388">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dehghani</surname><given-names>SM</given-names></name>
<name><surname>Basiratnia</surname><given-names>M</given-names></name>
<name><surname>Derakhshan</surname><given-names>A</given-names></name>
<name><surname>Mazidi</surname><given-names>M</given-names></name>
<name><surname>Malek-Hosseini</surname><given-names>SA</given-names></name>
</person-group>
<article-title>Urinary tract infection in children with cirrhosis waiting for liver transplantation</article-title>
<source>Saudi J Kidney Dis Transpl</source>
<year>2014</year>
<volume>25</volume>
<fpage>876</fpage>
<lpage>80</lpage>
</element-citation></ref>
<ref id="b11-cep-2026-00388">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>C</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Zhao</surname><given-names>H</given-names></name>
<name><surname>Wang</surname><given-names>G</given-names></name>
</person-group>
<article-title>Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019</article-title>
<source>Hepatol Int</source>
<year>2024</year>
<volume>18</volume>
<fpage>238</fpage>
<lpage>53</lpage>
</element-citation></ref>
<ref id="b12-cep-2026-00388">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shiau</surname><given-names>H</given-names></name>
<name><surname>Schraw</surname><given-names>JM</given-names></name>
<name><surname>Mysore</surname><given-names>K</given-names></name>
<name><surname>Cavallo</surname><given-names>L</given-names></name>
<name><surname>Harpavat</surname><given-names>S</given-names></name>
<name><surname>Lupo</surname><given-names>PJ</given-names></name>
<etal/>
</person-group>
<article-title>Characteristics of infections and their risk factors in children with biliary atresia</article-title>
<source>Clin Res Hepatol Gastroenterol</source>
<year>2023</year>
<volume>47</volume>
<fpage>102109</fpage>
</element-citation></ref>
<ref id="b13-cep-2026-00388">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Deutsch</surname><given-names>M</given-names></name>
<name><surname>Manolakopoulos</surname><given-names>S</given-names></name>
<name><surname>Andreadis</surname><given-names>I</given-names></name>
<name><surname>Giannaris</surname><given-names>M</given-names></name>
<name><surname>Kontos</surname><given-names>G</given-names></name>
<name><surname>Kranidioti</surname><given-names>H</given-names></name>
<etal/>
</person-group>
<article-title>Bacterial infections in patients with liver cirrhosis: clinical characteristics and the role of C-reactive protein</article-title>
<source>Ann Gastroenterol</source>
<year>2018</year>
<volume>31</volume>
<fpage>77</fpage>
<lpage>83</lpage>
</element-citation></ref>
<ref id="b14-cep-2026-00388">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Connert</surname><given-names>S</given-names></name>
<name><surname>Stremmel</surname><given-names>W</given-names></name>
<name><surname>Elsing</surname><given-names>C</given-names></name>
</person-group>
<article-title>Procalcitonin is a valid marker of infection in decompensated cirrhosis</article-title>
<source>Z Gastroenterol</source>
<year>2003</year>
<volume>41</volume>
<fpage>165</fpage>
<lpage>70</lpage>
</element-citation></ref>
<ref id="b15-cep-2026-00388">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Le Moine</surname><given-names>O</given-names></name>
<name><surname>Devi&#x000e8;re</surname><given-names>J</given-names></name>
<name><surname>Devaster</surname><given-names>JM</given-names></name>
<name><surname>Crusiaux</surname><given-names>A</given-names></name>
<name><surname>Durand</surname><given-names>F</given-names></name>
<name><surname>Bernuau</surname><given-names>J</given-names></name>
<etal/>
</person-group>
<article-title>Interleukin-6: an early marker of bacterial infection in decompensated cirrhosis</article-title>
<source>J Hepatol</source>
<year>1994</year>
<volume>20</volume>
<fpage>819</fpage>
<lpage>24</lpage>
</element-citation></ref>
<ref id="b16-cep-2026-00388">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lim</surname><given-names>LG</given-names></name>
<name><surname>Tan</surname><given-names>XX</given-names></name>
<name><surname>Woo</surname><given-names>SJ</given-names></name>
<name><surname>Dan</surname><given-names>YY</given-names></name>
<name><surname>Lee</surname><given-names>YM</given-names></name>
<name><surname>Lai</surname><given-names>V</given-names></name>
<etal/>
</person-group>
<article-title>Risk factors for mortality in cirrhotic patients with sepsis</article-title>
<source>Hepatol Int</source>
<year>2011</year>
<volume>5</volume>
<fpage>800</fpage>
<lpage>7</lpage>
</element-citation></ref>
<ref id="b17-cep-2026-00388">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Singh</surname><given-names>SK</given-names></name>
<name><surname>Poddar</surname><given-names>U</given-names></name>
<name><surname>Mishra</surname><given-names>R</given-names></name>
<name><surname>Srivastava</surname><given-names>A</given-names></name>
<name><surname>Yachha</surname><given-names>SK</given-names></name>
</person-group>
<article-title>Ascitic fluid infection in children with liver disease: time to change empirical antibiotic policy</article-title>
<source>Hepatol Int</source>
<year>2020</year>
<volume>14</volume>
<fpage>138</fpage>
<lpage>44</lpage>
</element-citation></ref>
<ref id="b18-cep-2026-00388">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>de Franchis</surname><given-names>R</given-names></name>
<name><surname>Bosch</surname><given-names>J</given-names></name>
<name><surname>Garcia-Tsao</surname><given-names>G</given-names></name>
<name><surname>Reiberger</surname><given-names>T</given-names></name>
<name><surname>Ripoll</surname><given-names>C</given-names></name>
<collab>Baveno VII Faculty</collab>
</person-group>
<article-title>Baveno VII - renewing consensus in portal hypertension</article-title>
<source>J Hepatol</source>
<year>2022</year>
<volume>76</volume>
<fpage>959</fpage>
<lpage>74</lpage>
</element-citation></ref>
<ref id="b19-cep-2026-00388">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Van der Merwe</surname><given-names>S</given-names></name>
<name><surname>Chokshi</surname><given-names>S</given-names></name>
<name><surname>Bernsmeier</surname><given-names>C</given-names></name>
<name><surname>Albillos</surname><given-names>A</given-names></name>
</person-group>
<article-title>The multifactorial mechanisms of bacterial infection in decompensated cirrhosis</article-title>
<source>J Hepatol</source>
<year>2021</year>
<volume>75 Suppl 1</volume>
<fpage>S82</fpage>
<lpage>100</lpage>
</element-citation></ref>
<ref id="b20-cep-2026-00388">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Copelan</surname><given-names>A</given-names></name>
<name><surname>Bahoura</surname><given-names>L</given-names></name>
<name><surname>Tardy</surname><given-names>F</given-names></name>
<name><surname>Kirsch</surname><given-names>M</given-names></name>
<name><surname>Sokhandon</surname><given-names>F</given-names></name>
<name><surname>Kapoor</surname><given-names>B</given-names></name>
</person-group>
<article-title>Etiology, diagnosis, and management of bilomas: a current update</article-title>
<source>Tech Vasc Interv Radiol</source>
<year>2015</year>
<volume>18</volume>
<fpage>236</fpage>
<lpage>43</lpage>
</element-citation></ref>
<ref id="b21-cep-2026-00388">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Alaniz</surname><given-names>C</given-names></name>
<name><surname>Regal</surname><given-names>RE</given-names></name>
</person-group>
<article-title>Spontaneous bacterial peritonitis: a review of treatment options</article-title>
<source>P T</source>
<year>2009</year>
<volume>34</volume>
<fpage>204</fpage>
<lpage>10</lpage>
</element-citation></ref>
<ref id="b22-cep-2026-00388">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kuppermann</surname><given-names>N</given-names></name>
</person-group>
<article-title>Occult bacteremia in young febrile children</article-title>
<source>Pediatr Clin North Am</source>
<year>1999</year>
<volume>46</volume>
<fpage>1073</fpage>
<lpage>109</lpage>
</element-citation></ref>
<ref id="b23-cep-2026-00388">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shane</surname><given-names>AL</given-names></name>
<name><surname>Mody</surname><given-names>RK</given-names></name>
<name><surname>Crump</surname><given-names>JA</given-names></name>
<name><surname>Tarr</surname><given-names>PI</given-names></name>
<name><surname>Steiner</surname><given-names>TS</given-names></name>
<name><surname>Kotloff</surname><given-names>K</given-names></name>
<etal/>
</person-group>
<article-title>2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea</article-title>
<source>Clin Infect Dis</source>
<year>2017</year>
<volume>65</volume>
<fpage>e45</fpage>
<lpage>80</lpage>
</element-citation></ref>
<ref id="b24-cep-2026-00388">
<label>24</label>
<element-citation publication-type="book">
<source>Urinary tract infection in under 16s: diagnosis and management</source>
<publisher-loc>London (UK)</publisher-loc>
<publisher-name>National Institute for Health and Care Excellence (NICE)</publisher-name>
<year>2022</year>
</element-citation></ref>
<ref id="b25-cep-2026-00388">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bolia</surname><given-names>R</given-names></name>
<name><surname>Srivastava</surname><given-names>A</given-names></name>
<name><surname>Marak</surname><given-names>R</given-names></name>
<name><surname>Yachha</surname><given-names>SK</given-names></name>
<name><surname>Poddar</surname><given-names>U</given-names></name>
</person-group>
<article-title>Prevalence and impact of bacterial infections in children with liver disease-a prospective study</article-title>
<source>J Clin Exp Hepatol</source>
<year>2018</year>
<volume>8</volume>
<fpage>35</fpage>
<lpage>41</lpage>
</element-citation></ref>
<ref id="b26-cep-2026-00388">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Albillos</surname><given-names>A</given-names></name>
<name><surname>Martin-Mateos</surname><given-names>R</given-names></name>
<name><surname>Van der Merwe</surname><given-names>S</given-names></name>
<name><surname>Wiest</surname><given-names>R</given-names></name>
<name><surname>Jalan</surname><given-names>R</given-names></name>
<name><surname>&#x000c1;lvarez-Mon</surname><given-names>M</given-names></name>
</person-group>
<article-title>Cirrhosis-associated immune dysfunction</article-title>
<source>Nat Rev Gastroenterol Hepatol</source>
<year>2022</year>
<volume>19</volume>
<fpage>112</fpage>
<lpage>34</lpage>
</element-citation></ref>
<ref id="b27-cep-2026-00388">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bruns</surname><given-names>T</given-names></name>
<name><surname>Zimmermann</surname><given-names>HW</given-names></name>
<name><surname>Stallmach</surname><given-names>A</given-names></name>
</person-group>
<article-title>Risk factors and outcome of bacterial infections in cirrhosis</article-title>
<source>World J Gastroenterol</source>
<year>2014</year>
<volume>20</volume>
<fpage>2542</fpage>
<lpage>54</lpage>
</element-citation></ref>
<ref id="b28-cep-2026-00388">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wiest</surname><given-names>R</given-names></name>
<name><surname>Lawson</surname><given-names>M</given-names></name>
<name><surname>Geuking</surname><given-names>M</given-names></name>
</person-group>
<article-title>Pathological bacterial translocation in liver cirrhosis</article-title>
<source>J Hepatol</source>
<year>2014</year>
<volume>60</volume>
<fpage>197</fpage>
<lpage>209</lpage>
</element-citation></ref>
<ref id="b29-cep-2026-00388">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Reichert</surname><given-names>MC</given-names></name>
<name><surname>Ripoll</surname><given-names>C</given-names></name>
<name><surname>Casper</surname><given-names>M</given-names></name>
<name><surname>Greinert</surname><given-names>R</given-names></name>
<name><surname>Vandieken</surname><given-names>E</given-names></name>
<name><surname>Gr&#x000fc;nhage</surname><given-names>F</given-names></name>
<etal/>
</person-group>
<article-title>Common NOD2 risk variants as major susceptibility factors for bacterial infections in compensated cirrhosis</article-title>
<source>Clin Transl Gastroenterol</source>
<year>2019</year>
<volume>10</volume>
<elocation-id>e00002</elocation-id>
</element-citation></ref>
<ref id="b30-cep-2026-00388">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bolia</surname><given-names>R</given-names></name>
<name><surname>Srivastava</surname><given-names>A</given-names></name>
<name><surname>Marak</surname><given-names>R</given-names></name>
<name><surname>Yachha</surname><given-names>SK</given-names></name>
<name><surname>Poddar</surname><given-names>U</given-names></name>
</person-group>
<article-title>Role of Procalcitonin and C-reactive protein as biomarkers of infection in children with liver disease</article-title>
<source>J Pediatr Gastroenterol Nutr</source>
<year>2016</year>
<volume>63</volume>
<fpage>406</fpage>
<lpage>11</lpage>
</element-citation></ref>
<ref id="b31-cep-2026-00388">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kalvandi</surname><given-names>G</given-names></name>
<name><surname>Honar</surname><given-names>N</given-names></name>
<name><surname>Geramizadeh</surname><given-names>B</given-names></name>
<name><surname>Ataollahi</surname><given-names>M</given-names></name>
<name><surname>Rahmani</surname><given-names>A</given-names></name>
<name><surname>Javaherizadeh</surname><given-names>H</given-names></name>
</person-group>
<article-title>Serum C-reactive protein in children with liver disease and ascites</article-title>
<source>Hepat Mon</source>
<year>2016</year>
<volume>16</volume>
<elocation-id>e38973</elocation-id>
</element-citation></ref></ref-list>
<sec sec-type="display-objects">
<title>Figures and Tables</title>
<fig id="f1-cep-2026-00388" position="float">
<label>Fig. 1.</label><caption><p>Kaplan-Meier analysis of native liver survival according to bacterial infection status. The dashed red line represents children with proven/suspected bacterial infection, and the solid blue line represents those with no documented bacterial infection. The vertical red line indicates 6 months after the first visit. HR, hazard ratio; CI, confidence interval.</p></caption>
<graphic xlink:href="cep-2026-00388f1.tif"/></fig>
<fig id="f2-cep-2026-00388" position="float">
<graphic xlink:href="cep-2026-00388f2.tif"/></fig>

<table-wrap id="t1-cep-2026-00388" position="float">
<label>Table 1.</label>
<caption><p>Demographic data and clinical characteristics of 150 patients with cirrhosis due to biliary atresia</p></caption>
<table rules="groups" frame="hsides">
<thead><tr>
<th align="left" valign="middle">Characteristic</th>
<th align="center" valign="middle">Total (n=150)</th>
<th align="center" valign="middle">Proven or suspected bacterial infection (n=65)</th>
<th align="center" valign="middle">Presumed viral infection (n=29)</th>
<th align="center" valign="middle">No documented infection (n=56)</th>
<th align="center" valign="middle"><italic>P</italic> value</th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="left">Female sex</td>
<td valign="top" align="center">77 (51.3)</td>
<td valign="top" align="center">35 (53.8)</td>
<td valign="top" align="center">16 (55.2)</td>
<td valign="top" align="center">26 (46.4)</td>
<td valign="top" align="center">0.65</td>
</tr>
<tr>
<td valign="top" align="left">Kasai operation</td>
<td valign="top" align="center">108 (72.0)</td>
<td valign="top" align="center">50 (76.9)</td>
<td valign="top" align="center">22 (75.9)</td>
<td valign="top" align="center">36 (64.3)</td>
<td valign="top" align="center">0.27</td>
</tr>
<tr>
<td valign="top" align="left">Age of Kasai operation (day)</td>
<td valign="top" align="center">91 (65&#x02013;123)</td>
<td valign="top" align="center">92 (69&#x02013;119)</td>
<td valign="top" align="center">73 (55&#x02013;103)</td>
<td valign="top" align="center">93 (62&#x02013;152)</td>
<td valign="top" align="center">0.15</td>
</tr>
<tr>
<td valign="top" align="left">Age at first visit at our institution (mo)</td>
<td valign="top" align="center">5.9 (3.4&#x02013;9.7)</td>
<td valign="top" align="center">5.2 (3&#x02013;9.3)</td>
<td valign="top" align="center">6 (3.4&#x02013;9.7)</td>
<td valign="top" align="center">7.9 (4.0&#x02013;10.7)</td>
<td valign="top" align="center">0.23</td>
</tr>
<tr>
<td valign="top" align="left">Decompensated cirrhosis</td>
<td valign="top" align="center">115 (77.2)</td>
<td valign="top" align="center">51 (79.7)</td>
<td valign="top" align="center">20 (69.0)</td>
<td valign="top" align="center">44 (78.6)</td>
<td valign="top" align="center">0.50</td>
</tr>
<tr>
<td valign="top" align="left">Significant portal hypertension</td>
<td valign="top" align="center">114 (76.0)</td>
<td valign="top" align="center">60 (92.3)</td>
<td valign="top" align="center">28 (97.0)</td>
<td valign="top" align="center">56 (100)</td>
<td valign="top" align="center">0.10</td>
</tr>
<tr>
<td valign="top" align="left">Pediatric end-stage liver disease score at the first visit</td>
<td valign="top" align="center">15 (9&#x02013;19)</td>
<td valign="top" align="center">15.5 (13&#x02013;20)</td>
<td valign="top" align="center">14 (11&#x02013;17)</td>
<td valign="top" align="center">16 (12&#x02013;21)</td>
<td valign="top" align="center">0.44</td>
</tr>
</tbody></table>
<table-wrap-foot>
<fn><p>Values are presented as number (%) or median (interquartile range).</p></fn>
</table-wrap-foot>
</table-wrap>

<table-wrap id="t2-cep-2026-00388" position="float">
<label>Table 2.</label>
<caption><p>Infectious episodes and diagnoses by category</p></caption>
<table rules="groups" frame="hsides">
<thead><tr>
<th align="left" valign="middle">Variable</th>
<th align="center" valign="middle">No. (%)</th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="left">Total fever episode (n)</td>
<td valign="top" align="center">222</td>
</tr>
<tr>
<td valign="top" align="left">Total diagnosis (n)</td>
<td valign="top" align="center">249</td>
</tr>
<tr>
<td valign="top" align="left">Total infection</td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Proven/suspected bacterial infection</td>
<td valign="top" align="center">143 (64.4)</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Presumed viral infection</td>
<td valign="top" align="center">79 (35.6)</td>
</tr>
<tr>
<td valign="top" align="left">Proven/suspected bacterial infection (diagnosis)</td>
<td valign="top" align="center">161 (64.6)</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Cholangitis</td>
<td valign="top" align="center">64 (39.7)</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Bacteremia/septicemia</td>
<td valign="top" align="center">36 (22.4)</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Infected biloma</td>
<td valign="top" align="center">16 (9.9)</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Ascites fluid infection<sup><xref rid="tfn1-cep-2026-00388" ref-type="table-fn">a)</xref></sup></td>
<td valign="top" align="center">13 (8.1)</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Infectious diarrhea</td>
<td valign="top" align="center">12 (7.4)</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Urinary tract infection</td>
<td valign="top" align="center">12 (7.4)</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Others (e.g., liver abscess, cellulitis)</td>
<td valign="top" align="center">8 (4.9)</td>
</tr>
<tr>
<td valign="top" align="left">Presumed viral infection (diagnosis)</td>
<td valign="top" align="center">88 (35.3)</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Gastroenteritis</td>
<td valign="top" align="center">22 (25.0)</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Upper respiratory tract infection</td>
<td valign="top" align="center">21 (23.8)</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Lower respiratory tract infection</td>
<td valign="top" align="center">16 (18.2)</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Others (e.g., viral exanthem, herpangina)</td>
<td valign="top" align="center">29 (33.0)</td>
</tr>
</tbody></table>
<table-wrap-foot>
<fn id="tfn1-cep-2026-00388"><label>a)</label><p>Ascites fluid infection included the following 3 subtypes: spontaneous bacterial peritonitis, culture-negative neutrocytic ascites, and monomicrobial nonneutrocytic bacterascites.</p></fn>
</table-wrap-foot>
</table-wrap>

<table-wrap id="t3-cep-2026-00388" position="float">
<label>Table 3.</label>
<caption><p>Univariate analysis of factors associated with proven or suspected bacterial infections</p></caption>
<table rules="groups" frame="hsides">
<thead><tr>
<th align="left" valign="middle">Variable</th>
<th align="center" valign="middle">Hazard ratio</th>
<th align="center" valign="middle">95% CI</th>
<th align="center" valign="middle"><italic>P</italic> value</th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="left">Pediatric end-stage liver disease score at the first visit</td>
<td valign="top" align="center">1.03</td>
<td valign="top" align="center">1.01&#x02013;1.07</td>
<td valign="top" align="center">0.05</td>
</tr>
<tr>
<td valign="top" align="left">Pediatric end-stage liver disease score at the fever episode</td>
<td valign="top" align="center">1.04</td>
<td valign="top" align="center">1.01&#x02013;1.08</td>
<td valign="top" align="center">0.02</td>
</tr>
<tr>
<td valign="top" align="left">Total bilirubin at the fever episode</td>
<td valign="top" align="center">1.04</td>
<td valign="top" align="center">1.01&#x02013;1.07</td>
<td valign="top" align="center">0.02</td>
</tr>
<tr>
<td valign="top" align="left">Direct bilirubin at the fever episode</td>
<td valign="top" align="center">1.05</td>
<td valign="top" align="center">1.004&#x02013;1.09</td>
<td valign="top" align="center">0.04</td>
</tr>
</tbody></table>
<table-wrap-foot>
<fn><p>CI, confidence interval.</p></fn>
</table-wrap-foot>
</table-wrap>

<table-wrap id="t4-cep-2026-00388" position="float">
<label>Table 4.</label>
<caption><p>Univariate and multivariate analyses of factors associated with proven or suspected bacterial infections during febrile episodes</p></caption>
<table rules="groups" frame="hsides">
<thead><tr>
<th align="left" valign="middle" rowspan="2">Variable</th>
<th align="center" valign="middle" colspan="3">Univariate analysis<hr/></th>
<th align="center" valign="middle" colspan="3">Multivariate analysis<hr/></th>
</tr><tr>
<th align="center" valign="middle">OR</th>
<th align="center" valign="middle">95% CI</th>
<th align="center" valign="middle"><italic>P</italic> value</th>
<th align="center" valign="middle">OR</th>
<th align="center" valign="middle">95% CI</th>
<th align="center" valign="middle"><italic>P</italic> value</th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="left">Fever &gt;39&#x000BA;C</td>
<td valign="top" align="center">0.82</td>
<td valign="top" align="center">0.45&#x02013;1.48</td>
<td valign="top" align="center">0.51</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">Change of mental status</td>
<td valign="top" align="center">1.60</td>
<td valign="top" align="center">0.68&#x02013;3.78</td>
<td valign="top" align="center">0.28</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">Shock</td>
<td valign="top" align="center">2.90</td>
<td valign="top" align="center">0.61&#x02013;13.46</td>
<td valign="top" align="center">0.18</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">Anemia</td>
<td valign="top" align="center">0.48</td>
<td valign="top" align="center">0.26&#x02013;0.89</td>
<td valign="top" align="center">0.02</td>
<td valign="top" align="center">0.78</td>
<td valign="top" align="center">0.13&#x02013;4.70</td>
<td valign="top" align="center">0.79</td>
</tr>
<tr>
<td valign="top" align="left">Abnormal white blood cells (&lt;5,000 or &gt;15,000 /mm<sup>3</sup>)</td>
<td valign="top" align="center">0.59</td>
<td valign="top" align="center">0.34&#x02013;1.04</td>
<td valign="top" align="center">0.07</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">Thrombocytopenia (&lt;140,000 /mm<sup>3</sup>)</td>
<td valign="top" align="center">1.25</td>
<td valign="top" align="center">0.70&#x02013;2.22</td>
<td valign="top" align="center">0.45</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">Procalcitonin (ng/mL)</td>
<td valign="top" align="center">1.05</td>
<td valign="top" align="center">0.94&#x02013;1.17</td>
<td valign="top" align="center">0.38</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">C-reactive protein (mg/L)</td>
<td valign="top" align="center">1.02</td>
<td valign="top" align="center">1.01&#x02013;1.03</td>
<td valign="top" align="center">&lt;0.01</td>
<td valign="top" align="center">1.02</td>
<td valign="top" align="center">1.01&#x02013;1.04</td>
<td valign="top" align="center"><bold>&lt;0.01</bold></td>
</tr>
<tr>
<td valign="top" align="left">Hypoalbuminemia (&lt;25 g/L)</td>
<td valign="top" align="center">0.62</td>
<td valign="top" align="center">0.34&#x02013;1.11</td>
<td valign="top" align="center">0.11</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">Total bilirubin</td>
<td valign="top" align="center">1.03</td>
<td valign="top" align="center">0.99&#x02013;1.06</td>
<td valign="top" align="center">0.10</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">Direct bilirubin</td>
<td valign="top" align="center">1.03</td>
<td valign="top" align="center">0.99&#x02013;1.07</td>
<td valign="top" align="center">0.16</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">Pediatric end-stage liver disease score at the fever episode</td>
<td valign="top" align="center">1.06</td>
<td valign="top" align="center">1.03&#x02013;1.10</td>
<td valign="top" align="center">&lt;0.01</td>
<td valign="top" align="center">1.11</td>
<td valign="top" align="center">1.02&#x02013;1.19</td>
<td valign="top" align="center"><bold>0.01</bold></td>
</tr>
</tbody></table>
<table-wrap-foot>
<fn><p>OR, odds ratio; CI, confidence interval.</p>
<p>Boldface indicates a statistically significant difference with <italic>P</italic>&lt;0.05.</p></fn>
</table-wrap-foot>
</table-wrap>

<table-wrap id="t5-cep-2026-00388" position="float">
<label>Table 5.</label>
<caption><p>Univariate and multivariate analyses of factors associated with undergoing liver transplantation</p></caption>
<table rules="groups" frame="hsides">
<thead><tr>
<th align="left" valign="middle" rowspan="2">Variable</th>
<th align="center" valign="middle" colspan="3">Univariate analysis<hr/></th>
<th align="center" valign="middle" colspan="3">Multivariate analysis<hr/></th>
</tr><tr>
<th align="center" valign="middle">HR</th>
<th align="center" valign="middle">95% CI</th>
<th align="center" valign="middle"><italic>P</italic> value</th>
<th align="center" valign="middle">HR</th>
<th align="center" valign="middle">95% CI</th>
<th align="center" valign="middle"><italic>P</italic> value</th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="left">Proven/suspected bacterial infection</td>
<td valign="top" align="center">2.71</td>
<td valign="top" align="center">1.70&#x02013;4.32</td>
<td valign="top" align="center"><bold>&lt;0.01</bold></td>
<td valign="top" align="center">2.68</td>
<td valign="top" align="center">1.60&#x02013;4.49</td>
<td valign="top" align="center"><bold>&lt;0.01</bold></td>
</tr>
<tr>
<td valign="top" align="left">PELD score at first visit (ref.: &lt;15)</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;15&#x02013;20</td>
<td valign="top" align="center">1.75</td>
<td valign="top" align="center">1.04&#x02013;2.96</td>
<td valign="top" align="center"><bold>0.04</bold></td>
<td valign="top" align="center">1.51</td>
<td valign="top" align="center">0.82&#x02013;2.78</td>
<td valign="top" align="center">0.19</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;&gt;20</td>
<td valign="top" align="center">2.51</td>
<td valign="top" align="center">1.39&#x02013;4.51</td>
<td valign="top" align="center"><bold>&lt;0.01</bold></td>
<td valign="top" align="center">1.76</td>
<td valign="top" align="center">0.92&#x02013;3.36</td>
<td valign="top" align="center">0.09</td>
</tr>
<tr>
<td valign="top" align="left">PELD score at last visit before the predefined clinical outcomes<sup><xref rid="tfn2-cep-2026-00388" ref-type="table-fn">a)</xref></sup> (ref.: &lt;15)</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;15&#x02013;20</td>
<td valign="top" align="center">2.08</td>
<td valign="top" align="center">1.14&#x02013;3.78</td>
<td valign="top" align="center"><bold>0.02</bold></td>
<td valign="top" align="center">1.62</td>
<td valign="top" align="center">0.80&#x02013;3.26</td>
<td valign="top" align="center">0.18</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;&gt;20</td>
<td valign="top" align="center">2.41</td>
<td valign="top" align="center">1.43&#x02013;4.08</td>
<td valign="top" align="center"><bold>&lt;0.01</bold></td>
<td valign="top" align="center">1.42</td>
<td valign="top" align="center">0.78&#x02013;2.59</td>
<td valign="top" align="center">0.25</td>
</tr>
<tr>
<td valign="top" align="left">Past history of infection before referral to our center</td>
<td valign="top" align="center">0.71</td>
<td valign="top" align="center">0.45&#x02013;1.13</td>
<td valign="top" align="center">0.17</td>
<td valign="top" align="center">0.83</td>
<td valign="top" align="center">0.50&#x02013;1.37</td>
<td valign="top" align="center">0.46</td>
</tr>
</tbody></table>
<table-wrap-foot>
<fn><p>HR, hazard ratio; CI, confidence interval; PELD, pediatric end-stage liver disease; ref., reference.</p></fn>
<fn id="tfn2-cep-2026-00388"><label>a)</label><p>Predefined clinical outcomes were liver transplantation, the last outpatient visit for patients who survived with a native liver, death, and loss to follow-up.</p></fn>
<fn><p>Boldface indicates a statistically significant difference with <italic>P</italic>&lt;0.05.</p></fn>
</table-wrap-foot>
</table-wrap>

<table-wrap id="t6-cep-2026-00388" position="float">
<label>Table 6.</label>
<caption><p>Comparison of associated clinical factors according to clinical outcomes</p></caption>
<table rules="groups" frame="hsides">
<thead><tr>
<th align="left" valign="middle">Variable</th>
<th align="center" valign="middle">LT (n=81)</th>
<th align="center" valign="middle">Survival with native liver (n=36)</th>
<th align="center" valign="middle">Death (n=12)</th>
<th align="center" valign="middle">Loss to follow-up (n =21)</th>
<th align="center" valign="middle"><italic>P</italic> value</th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="left">Sex: female</td>
<td valign="top" align="center">45 (55.5)</td>
<td valign="top" align="center">15 (41.6)</td>
<td valign="top" align="center">7 (58.3)</td>
<td valign="top" align="center">10 (47.6)</td>
<td valign="top" align="center">0.52</td>
</tr>
<tr>
<td valign="top" align="left">Kasai operation</td>
<td valign="top" align="center">53 (65.4)</td>
<td valign="top" align="center">34 (94.4)</td>
<td valign="top" align="center">9 (75)</td>
<td valign="top" align="center">12 (57.1)</td>
<td valign="top" align="center"><bold>0.008</bold></td>
</tr>
<tr>
<td valign="top" align="left">Age at Kasai operation &gt; 90 days</td>
<td valign="top" align="center">27 (54)</td>
<td valign="top" align="center">12 (38.7)</td>
<td valign="top" align="center">5(55.5)</td>
<td valign="top" align="center">7 (33.3)</td>
<td valign="top" align="center">0.37</td>
</tr>
<tr>
<td valign="top" align="left">Past history of infection before referral to our center</td>
<td valign="top" align="center">32 (39.5)</td>
<td valign="top" align="center">14 (38.8)</td>
<td valign="top" align="center">6 (50)</td>
<td valign="top" align="center">5 (23.8)</td>
<td valign="top" align="center">0.45</td>
</tr>
<tr>
<td valign="top" align="left">Decompensated cirrhosis</td>
<td valign="top" align="center">74 (91.3)</td>
<td valign="top" align="center">11 (30.5)</td>
<td valign="top" align="center">12 (100)</td>
<td valign="top" align="center">18 (85.7)</td>
<td valign="top" align="center"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">PELD score at first visit</td>
<td valign="top" align="center">15 (12&#x02013;20)</td>
<td valign="top" align="center">7.5 (0&#x02013;14)</td>
<td valign="top" align="center">17 (14&#x02013;20)</td>
<td valign="top" align="center">18.5 (12&#x02013;22)</td>
<td valign="top" align="center"><bold>&lt;0.001</bold></td>
</tr>
</tbody></table>
<table-wrap-foot>
<fn><p>Values are presented as number (%) or median (interquartile range).</p>
<p>LT, liver transplantation; PELD, pediatric end-stage liver disease.</p>
<p>Boldface indicates a statistically significant difference with <italic>P</italic>&lt;0.05.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
</back></article>